LENZ Therapeutics, Inc.(US:LENZ)2026-03-24 20:10Financial Position - LENZ has $292.3 million in cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2025, which is expected to fund operations to positive operating cash flow [449]. - The company incurred an accumulated deficit of $227.1 million as of December 31, 2025, primarily due to research and development and selling, general, and administrative costs [450]. - As of December 31, 2025, the company had $292.3 million in cash, cash equivalents, restricted cash, and marketable securities, with an accumulated deficit of $227.1 million [483]. - Net cash used in operating activities for the year ended December 31, 2025 was $69.2 million, resulting from a net loss of $82.1 million [491]. - Cash used in investing activities for the year ended December 31, 2025 was $75.7 million, primarily due to $280.8 million in purchases of marketable securities [493]. - Cash provided by financing activities for the year ended December 31, 2025 was $149.7 million, mainly from net proceeds of $147.7 million from common stock sold under the Sales Agreement [495]. Product Development and Commercialization - VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, has a U.S. market opportunity exceeding $3 billion [447]. - The commercial launch of VIZZ began in August 2025, with product availability in retail pharmacies starting in November 2025 [448]. - Lotus submitted a New Drug Application for VIZZ in South Korea on December 1, 2025, marking the first submission under the Lotus License [464]. - A Marketing Authorization Application for VIZZ was submitted to the European Medicines Agency on March 10, 2026, representing the fifth ex-U.S. regulatory submission [465]. - The company expects product sales and associated costs to increase in 2026 as the commercialization of VIZZ continues [462]. Revenue and Expenses - Product sales, net for the year ended December 31, 2025 were $1.6 million, driven by approximately 20,000 paid prescriptions filled after FDA approval of VIZZ in July 2025 [475]. - License revenue increased to $17.5 million for the year ended December 31, 2025, due to upfront payments under the Lotus and Théa Licenses and regulatory milestones under the CORXEL License [476]. - Selling, general and administrative expenses rose by $62.3 million, or 216%, to $91.1 million for the year ended December 31, 2025, primarily due to increased employee salaries and marketing costs [478]. - Research and development expenses decreased by $11.1 million, or 37%, to $18.7 million for the year ended December 31, 2025, mainly due to reduced clinical trial costs [481]. - Other income, net for the year ended December 31, 2025 was $9.5 million, an increase from $8.8 million in 2024, driven by additional interest income [482]. Company Operations and Future Outlook - The company expects to continue incurring significant expenses and operating losses in the early stages of VIZZ commercialization [483]. - The company has built a cross-functional commercial team and expanded its sales force, leading to increased selling, general, and administrative expenses [462]. - The company does not anticipate paying dividends in the future, having historically paid none except for a special dividend prior to a merger [507]. Accounting and Reporting - The company is classified as an emerging growth company under the JOBS Act, allowing it to rely on certain exemptions from public company disclosure requirements until December 31, 2026 [508]. - The market value of the company's stock held by non-affiliates was less than $700 million as of June 30, 2025, qualifying it as a smaller reporting company [511]. - The company has not experienced material differences between estimates and actual results in its consolidated financial statements historically [501]. - The company uses a simplified method to calculate the expected term for stock options due to insufficient historical exercise data [505]. - The expected volatility for stock options is derived from comparable publicly traded companies due to limited historical data [506]. - Recent accounting pronouncements are discussed in Note 2 of the consolidated financial statements [512].